Characterization of the mitofusin 2 R94W mutation in a knock-in mouse model

Journal of the Peripheral Nervous System

Volumn 19, Issue 2, 2014, Pages 152-164

  Strickland, Alleene V ^a   Rebelo, Adriana P ^a   Zhang, Fan ^a   Price, Justin ^a   Bolon, Brad ^b   Silva, Jose P ^a   Wen, Rong ^c   Züchner, Stephan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Charcot Marie Tooth; Mitofusin 2; Mouse model; Peripheral disease model

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALBINDIN; CRE RECOMBINASE; MITOFUSIN 2; ARGININE; GUANOSINE TRIPHOSPHATASE; MFN2 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; TRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXPLORATORY BEHAVIOR TEST; FIBROBLAST; GENE MUTATION; GENETIC ASSOCIATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; MOUSE; NERVE FIBER DEGENERATION; NEWBORN; NONHUMAN; OPEN FIELD TEST; PERIPHERAL NEUROPATHY; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURKINJE CELL; SCIATIC NERVE; ANIMAL; CELL CULTURE; DISEASE MODEL; ESCAPE BEHAVIOR; EXPLORATORY BEHAVIOR; GENETICS; IN VITRO STUDY; METABOLISM; MITOCHONDRION; MOTOR ACTIVITY; MUSCLE STRENGTH; OXYGEN CONSUMPTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POINT MUTATION; PSYCHOMOTOR PERFORMANCE; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, NEWBORN; ARGININE; CELLS, CULTURED; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODELS, ANIMAL; ESCAPE REACTION; EXPLORATORY BEHAVIOR; FIBROBLASTS; GTP PHOSPHOHYDROLASES; HUMANS; IN VITRO TECHNIQUES; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MOTOR ACTIVITY; MUSCLE STRENGTH; OXYGEN CONSUMPTION; POINT MUTATION; PSYCHOMOTOR PERFORMANCE; TRYPTOPHAN;

EID: 84925352212     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12066     Document Type: Article

References (36)

1. Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, Daugaard JR, Lloberas J, Camps M, Zierath JR, Rabasa-Lhoret R, Wallberg-Henriksson H, Laville M, Palacín M, Vidal H, Rivera F, Brand M, Zorzano A, Palacin M, Vidal H, Rivera F, Brand M, Antonio Z (2003). Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem 278:17190-17197. DOI: 10.1074/jbc.M212754200.
2. Baloh RH, Schmidt RE, Pestronk A, Milbrandt J (2008). Mitochondrial dynamics and peripheral neuropathy. Neuroscientist 14:12-18. DOI: 10.1177/1073858407307354.
3. Baloh RH, Schmidt RE, Pestronk A, et al. (2007). Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci 27:422-430. DOI: 10.1523/JNEUROSCI.4798-06.2007.
4. Braathen GJ, Sand JC, Lobato A, Hoyer H, Russell MB (2010). MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families. BMC Med Genet 11:48. DOI: 10.1186/1471-2350-11-48.
5. Cartoni R, Arnaud E, Médard J-J, Poirot O, Courvoisier DS, Chrast R, Martinou J-C (2010). Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. Brain 133(Pt 5):1460-1469. DOI: 10.1093/brain/awq082.
6. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003). Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160:189-200. DOI: 10.1083/jcb.200211046.
7. Chen H, Chomyn A, Chan DC (2005). Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 280:26185-26192. DOI: 10.1074/jbc.M503062200.
8. Chen H, McCaffery JM, Chan DC (2007). Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 130:548-562. DOI: 10.1016/j.cell.2007.06.026.
9. Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM, Chan DC (2010). Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141:280-289. DOI: 10.1016/j.cell.2010.02.026.
10. De Brito OM, Scorrano L (2008). Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456:605-610. DOI: 10.1038/nature07534.
11. Detmer SA, Chan DC (2007). Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations. J Cell Biol 176:405-414. DOI: 10.1083/jcb.200611080.
12. Detmer SA, Vande Velde C, Cleveland DW, Chan DC (2008). Hindlimb gait defects due to motor axon loss and reduced distal muscles in a transgenic mouse model of Charcot-Marie-Tooth type 2A. Hum Mol Genet 17:367-375. DOI: 10.1093/hmg/ddm314.
13. Engelfried K, Vorgerd M, Hagedorn M, Haas G, Gilles J, Epplen JT, Meins M (2006). Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2). BMC Med Genet 7:53. DOI: 10.1186/1471-2350-7-53.
14. Eura Y, Ishihara N, Yokota S, Mihara K (2003). Two mitofusin proteins, mammalian homologues of FZO, with distinct functions are both required for mitochondrial fusion. J Biochem 134:333-344. DOI: 10.1093/jb/mvg150.
15. Feely SME, Laurà M, Siskind CE, Sottile S, Davis M, Gibbons VS, Reilly MM, Shy ME (2011). MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 76:1690-1696. DOI: 10.1212/WNL.0b013e31821a441e.
16. Gall JM, Wang Z, Liesa M, Molina A, Havasi A, Schwartz JH, Shirihai O, Borkan SC, Bonegio RGB (2012). Role of mitofusin 2 in the renal stress response. PLoS One 7:e31074. DOI: 10.1371/journal.pone.0031074.
17. Gegg ME, Cooper JM, Chau K-Y, Rojo M, Schapira AHV, Taanman J-W (2010). Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet 19:4861-4870. DOI: 10.1093/hmg/ddq419.
18. Girard M, Larivière R, Parfitt DA, Deane EC, Gaudet R, Nossova N, Blondeau F, Prenosil G, Vermeulen EGM, Duchen MR, Richter A, Shoubridge EA, Gehring K, McKinney RA, Brais B, Chapple JP, McPherson PS (2012). Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Proc Natl Acad Sci USA 109:1661-1666. DOI: 10.1073/pnas.1113166109.
19. Guillet V, Gueguen N, Verny C, Ferre M, Homedan C, Loiseau D, Procaccio V, Amati-Bonneau P, Bonneau D, Reynier P, Chevrollier A (2010). Adenine nucleotide translocase is involved in a mitochondrial coupling defect in MFN2-related Charcot-Marie-Tooth type 2A disease. Neurogenetics 11:127-133. DOI: 10.1007/s10048-009-0207-z.
20. Hales KG, Fuller MT (1997). Developmentally regulated mitochondrial fusion mediated by a conserved, novel, predicted GTPase. Cell 90:121-129.
21. Hikida T, Kitabatake Y, Pastan I, Nakanishi S (2003). Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci USA 100:6169-6173. DOI: 10.1073/pnas.0631749100.
22. Kerr B, Silva PA, Walz K, Young JI (2010). Unconventional transcriptional response to environmental enrichment in a mouse model of Rett syndrome. PLoS One 5:e11534. DOI: 10.1371/journal.pone.0011534.
23. Kijima K, Numakura C, Izumino H, Umetsu K, Nezu A, Shiiki T, Ogawa M, Ishizaki Y, Kitamura T, Shozawa Y, Hayasaka K (2005). Mitochondrial GTPase mitofusin 2 mutation in Charcot-Marie-Tooth neuropathy type 2A. Hum Genet 116:23-27. DOI: 10.1007/s00439-004-1199-2.
24. Lawson VH, Graham BV, Flanigan KM (2005). Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 65:197-204. DOI: 10.1212/01.wnl.0000168898.76071.70.
25. Lee S, Sterky FH, Mourier A, Terzioglu M, Cullheim S, Olson L, Larsson N-G (2012). Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons. Hum Mol Genet 1-9. DOI: 10.1093/hmg/dds352.
26. Loiseau D, Chevrollier A, Verny C, Guillet V, Gueguen N, Pou de Crescenzo MA, Ferre M, Malinge MC, Guichet A, Nicolas G, Amati-Bonneau P, Malthiery Y, Bonneau D, Reynier P (2007). Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease. Ann Neurol 61:315-323. DOI: 10.1002/ana.21086.
27. Misko AL, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH (2010). Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci 30:4232-4240. DOI: 10.1523/JNEUROSCI.6248-09.2010.
28. Misko AL, Sasaki Y, Tuck E, Milbrandt J, Baloh RH (2012). Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J Neurosci 32:4145-4155. DOI: 10.1523/JNEUROSCI.6338-11.2012.
29. Papanicolaou KN, Khairallah RJ, Ngoh GA, Chikando A, Luptak I, O'Shea KM, Riley DD, Lugus JJ, Colucci WS, Lederer WJ, Stanley WC, Walsh K (2011). Mitofusin-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes. Mol Cell Biol 31:1309-1328. DOI: 10.1128/MCB.00911-10.
30. Pham AH, Meng S, Chu QN, Chan DC (2012). Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum Mol Genet 12:1-10. DOI: 10.1093/hmg/dds311.
31. Pich S, Bach D, Briones P, Liesa M, Camps M, Testar X, Palacín M, Zorzano A (2005). The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. Hum Mol Genet 14:1405-1415. DOI: 10.1093/hmg/ddi149.
32. Rizzuto R (1998). Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science 280:1763-1766. DOI: 10.1126/science.280.5370.1763.
33. Verhoeven K, Claeys KG, Züchner S, Schröder JM, Weis J, Ceuterick C, Jordanova A, Nelis E, De Vriendt E, Van Hul M, Seeman P, Mazanec R, Saifi GM, Szigeti K, Mancias P, Butler IJ, Kochanski A, Ryniewicz B, De Bleecker J, Van den Bergh P, Verellen C, Van Coster R, Goemans N, Auer-Grumbach M, Robberecht W, Milic Rasic V, Nevo Y, Tournev I, Guergueltcheva V, Roelens F, Vieregge P, Vinci P, Moreno MT, Christen H-JJ, Shy ME, Lupski JR, Vance JM, De Jonghe P, Timmerman V (2006). MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 129(Pt 8):2093-2102. DOI: 10.1093/brain/awl126.
34. Westermann B (2012). Bioenergetic role of mitochondrial fusion and fission. Biochim Biophys Acta 6-11. DOI: 10.1016/j.bbabio.2012.02.033.
35. Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, De Jonghe P, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schröder JM, Vance JM, Battologlu E (2004). Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36:449-451. DOI: 10.1038/ng1341.
36. Züchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR, Van Stavern G, Krajewski KM, Stajich J, Tournev I, Verhoeven K, Langerhorst CT, De Visser M, Baas F, Bird T, Timmerman V, Shy ME, Vance JM (2006). Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 59:276-281. DOI: 10.1002/ana.20797.